Open medicine (Warsaw, Poland) · 2026
Safety study of sitagliptin combined with metoprolol on the treatment of elderly patients with type 2 diabetes mellitus and hypertension.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dai Xiaoqing, Yu Jiali
Аннотация
OBJECTIVES: Sitagliptin is a standard therapeutic option for type 2 diabetes mellitus (T2DM), while metoprolol is an antihypertensive agent. This study aimed to assess the safety of their combination therapy in elderly patients with T2DM and hypertension.
METHODS: Medical data of 52 elderly patients with T2DM and hypertension from June 2021 to March 2024 were retrospectively collected. According to different treatment methods, 52 patients were categorized into the sitagliptin + metoprolol group (n=26) and the sitagliptin group (n=26). After a 12-week treatment period, the baseline characteristics, therapeutic efficacy and biochemical indicators were analyzed between groups.
RESULTS: After 12-week treatment, both groups exhibited significant improvements in therapeutic efficacy, immune-inflammatory status, coagulation function, and liver-kidney function (p<0.05). Compared with the sitagliptin group, the sitagliptin + metoprolol group showed better therapeutic efficacy, with lower FPG, HbA1c, SBP, and DBP levels (p<0.05). The combination group also achieved greater improvements in immune-inflammation, coagulation, and liver-kidney function (lower CRP, NLR, Fib, Scr and BUN, as well as higher PT and APTT) (p<0.05). There was no significant difference in incidence of adverse event between the two groups (p>0.05).
CONCLUSIONS: Short-term observation indicates that sitagliptin combined with metoprolol can improve blood glucose, blood pressure, inflammation, coagulation, and liver-kidney function in elderly patients with T2DM and hypertension, without a significant increase in the risk of adverse reactions during short-term follow-up. However, as a single-center, small-sample retrospective study, the present findings should be interpreted as preliminary clinical evidence.
METHODS: Medical data of 52 elderly patients with T2DM and hypertension from June 2021 to March 2024 were retrospectively collected. According to different treatment methods, 52 patients were categorized into the sitagliptin + metoprolol group (n=26) and the sitagliptin group (n=26). After a 12-week treatment period, the baseline characteristics, therapeutic efficacy and biochemical indicators were analyzed between groups.
RESULTS: After 12-week treatment, both groups exhibited significant improvements in therapeutic efficacy, immune-inflammatory status, coagulation function, and liver-kidney function (p<0.05). Compared with the sitagliptin group, the sitagliptin + metoprolol group showed better therapeutic efficacy, with lower FPG, HbA1c, SBP, and DBP levels (p<0.05). The combination group also achieved greater improvements in immune-inflammation, coagulation, and liver-kidney function (lower CRP, NLR, Fib, Scr and BUN, as well as higher PT and APTT) (p<0.05). There was no significant difference in incidence of adverse event between the two groups (p>0.05).
CONCLUSIONS: Short-term observation indicates that sitagliptin combined with metoprolol can improve blood glucose, blood pressure, inflammation, coagulation, and liver-kidney function in elderly patients with T2DM and hypertension, without a significant increase in the risk of adverse reactions during short-term follow-up. However, as a single-center, small-sample retrospective study, the present findings should be interpreted as preliminary clinical evidence.